Ashler et Manson SA (MLAEM) fair value: what the stock is really worth
We calculate from audited financials what Ashler et Manson SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
Financial Services · FR · Market cap €9.0M
At a glance
AEAshler et Manson SAMLAEM · PA
Price from Sep 4, 2026€2.20
Fair Value€0.3000
Upside−86.4% ⚠
Quality69/100
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
A solid business, but trading 633% above our fair value of €0.3000.
As of Sep 11, 2026, the fair value of Ashler et Manson SA is €0.3000 per share against a price of €2.20, so the fair value sits 86% below the price. A model estimate from reported figures, not an analyst target.
!Mixed Growth (revenue 3y +51.1 %/yr)
✓Solidly profitable · 15.6% net margin
✓Low debt
!Trails peers (4/11)
!Moderate moat 48/100
!Evidence only low, so the estimate is less certain
!Weak on past: 19 out of 100
Evidence: LowRange €0.2200 to €0.3700
Fair value as of: Sep 11, 2026
From 4 valuation models · updated today
Share price −22.5% over the past month.
This is the short version. In the app for Ashler et Manson SA:
Watch Ashler et Manson SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (€0.3700). The favourable scenario is already priced in.
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 11, 2026.
How to read this chart
60‑month range €1.60 – €4.58 · fair‑value band €0.2200 – €0.3700 · the €2.20 price screens above the €0.3000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 11, 2026.
Ashler et Manson SA (MLAEM) currently trades at €2.20, while our model-based Fair Value estimate is €0.3000, implying the stock looks roughly 633.1% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Financial Services sector. Bull case: the Asset-Based group reads highest at a median of €0.2900 per share, and 0 of the 4 models we run sit above the €2.20 price. Bear case: the Multiples group reads lowest at €0.2600, and 4 of the 4 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Ashler et Manson SA generated revenue of €406K at a net margin of 15.6%. It earns a return on equity of 4.7%. The stock trades on a trailing P/E of 55.0. Fundamentals as of Sep 11, 2026
Scenario range: €0.2200 (bear) to €0.3700 (bull), the price of €2.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 33% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at −43% fair-value upside, at −86%, MLAEM screens richer than that median.
Fair Value models
Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (€0.0500 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Highest evidence
Residual Income best evidence€0.2900€0.2800€0.230071
P/E Multiple€0.1900€0.2600€0.320063
P/B Multiple€0.2500€0.3400€0.420055
All 4 models by family
Multiples
P/E Multiple€0.1900€0.2600€0.320063
P/B Multiple€0.2500€0.3400€0.420055
Asset-Based
NCAV (Graham)€0.2200€0.2900€0.430054
Economic Profit
Residual Income best evidence€0.2900€0.2800€0.230071
Widest divergence: Asset-Based (€0.2900) versus Multiples (€0.2600). Highest evidence: Residual Income (71).
Notify me when MLAEM reaches fair value
Put MLAEM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio55.0
P/S ratio8.60P/E × margin
EPS (TTM)€0.0400price ÷ EPS = P/E 55.0
Net margin15.6%FY2024
Return on equity4.7%TTM
Return on assets (EBIT)2.1%avg 5y
More key figures
Profitability
Operating margin21.5%TTM
Growth
Revenue (TTM)€406KTTM
Balance sheet & cash flow
Net debt€176KFY2024
Figures from reported company fundamentals · as of Sep 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality69/100
Of which business quality 64
· Market factors (momentum, volatility) 33
Profitability34
Margins and returns on capital today
Quality Growth51
Are margins and returns improving?
Fin. Strength74
Balance sheet, leverage, solvency risk
Investment100
Disciplined investing over empire-building
Low Volatility50
Calm price path (market factor)
Momentum26
Price trend over the last 3–12 months (market factor)
52W Momentum26
Distance to the 52-week high (market factor)
Net Issuance82
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Ashler et Manson SA, together with its subsidiaries, operates as a a mortgage and loan insurance brokerage company in France. The company offers amortizing, bullet, and bridge loans; and mortgage loan insurance products. Ashler et Manson SA was founded in 2003 and is based in Bordeaux, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Ashler et Manson SA reported revenue of €406K in FY2024 versus €157K in FY2020, a compound +26.9%/yr. Reported net income was €63.5K in FY2024, compounding +53.8%/yr from FY2020. FY2020 was a trough year, so the rate overstates the trend.
Growth Quality 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
€406K
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+51.1%
Avg. revenue growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.4%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−17.1%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−17.1%
Dividend yield0.0%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −17.1% vs 10Y −0.1%, flattening
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8.4% (2019) → 19.6% (2024) · rising
Worst earnings drop188% (2015) (loss year, drop beyond 100%) · in EUR
⚠ Revenue per share shrinking 3.4%/yr over ~8Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 0
FUTURE0· sector 66
PAST19· sector 60
HEALTH93· sector 88
DIVIDEND0· sector 79
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Insurance Brokers stocks, each showing price versus our Fair Value estimate (as of Sep 11, 2026).
Is Ashler et Manson SA (MLAEM) overvalued or undervalued?
As of Sep 11, 2026, our model estimates a fair value of €0.3000 versus the last price from Sep 4, 2026 of €2.20, about −86% upside (overvalued).
What is the fair value of MLAEM?
Our model-based fair value for Ashler et Manson SA is €0.3000 (as of Sep 11, 2026), built from audited fundamentals. Last price (from Sep 4, 2026): €2.20.
What is the quality score of MLAEM?
Ashler et Manson SA has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ashler et Manson SA (MLAEM)?
Our model-based price target is the fair value of €0.3000 (as of Sep 11, 2026) from 4 valuation models. Cautious scenario €0.2200, optimistic scenario €0.3700. It is a calculation from audited fundamentals, not an analyst target.
What is the Ashler et Manson SA stock forecast for 2026?
Our models put fair value at €0.3000, about −86% upside versus the last price from Sep 4, 2026 of €2.20 (overvalued). Cautious scenario €0.2200, optimistic scenario €0.3700. The calculation is refreshed regularly with new filings.
What is the revenue of Ashler et Manson SA (MLAEM)?
Ashler et Manson SA reported trailing-twelve-month revenue of about €406K (latest available figure, as of Sep 11, 2026).
What is the net profit margin of MLAEM?
The net profit margin of Ashler et Manson SA is about 15.6%, meaning it keeps roughly 15.6% of revenue as net income. Based on the latest reported figures.
What is the intrinsic value of Ashler et Manson SA (MLAEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ashler et Manson SA it is €0.3000 per share (as of Sep 11, 2026), against a price of €2.20. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Ashler et Manson SA stock overvalued or undervalued in 2026?
As of Sep 11, 2026, MLAEM trades above its calculated fair value: price €2.20, fair value €0.3000, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MLAEM?
No. The price is what the market pays today (€2.20); the fair value is what the company's own numbers justify (€0.3000). For Ashler et Manson SA the two are €1.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ashler et Manson SA worth?
The market values Ashler et Manson SA at about €9.0M (market capitalisation, as of Sep 11, 2026). Per share that is €2.20; our models calculate a fair value of €0.3000 per share.
What do the bullish and bearish scenarios say about MLAEM?
Our models span a range for Ashler et Manson SA: cautious scenario €0.2200, base €0.3000, optimistic €0.3700 per share (as of Sep 11, 2026, price €2.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MLAEM?
Ashler et Manson SA trades at a price-to-earnings ratio of 55.0 (as of Sep 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.3000 is built from several models across several years. Other multiples: P/B 7.6, P/S 25.6.
How solid is the balance sheet of Ashler et Manson SA (MLAEM)?
Balance-sheet figures for Ashler et Manson SA (as of Sep 11, 2026): return on equity 4.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is MLAEM from its 52-week high?
Ashler et Manson SA trades at €2.20, about 33% below its 52-week high of €3.28 and 20% above the low of €1.84 (as of Sep 11, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3000 is for.
Which stocks are comparable to Ashler et Manson SA?
From the same area (Financial Services) we also value Marsh & McLennan Companies, Inc, Aon plc, Arthur J. Gallagher & Co, Willis Towers Watson Public Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ashler et Manson SA stock attractive at the current price?
The data as of Sep 11, 2026: price €2.20, calculated fair value €0.3000 (−86%), Quality Score 69/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MLAEM calculated?
We run Ashler et Manson SA through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.3000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. Ashler et Manson SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed
Watch Ashler et Manson SA in the live analysis
One click puts Ashler et Manson SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
